4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Grace Therapeutics, Inc. (GRCE) operates in the Biotechnology industry and is headquartered in Princeton, United States with about 5 employees. Its market capitalization is roughly $42 million. In the fiscal year ended 2026-03-31, GRCE reported $0M in revenue and ($8M) in net income.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Gross Profit | — | — | — | — | $0M |
| Operating Income (EBIT) | ($11M) | ($17M) | ($13M) | ($52M) | — |
| Net Income | ($8M) | ($10M) | ($13M) | ($42M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($16M) | ($3M) | ($2M) | ($2M) | ($3M) | — |
| Net Income | ($16M) | ($1M) | ($2M) | ($1M) | ($3M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | $67M | $72M | $73M | $79M | — |
| Total Liabilities | $3M | $5M | $12M | $11M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GRCE viewer.
About TickerBase · Data methodology & sources · Privacy · Terms